Association between exposure to metformin and risk of myeloproliferative neoplasm according to duration of metformin exposure
| Subgroup . | Cases, n . | Controls, n . | OR∗ (95% CI) . | Adjusted OR† (95% CI) . |
|---|---|---|---|---|
| Exposure | ||||
| Never-use | 3548 | 17 507 | 1.0 (reference) | 1.0 (reference) |
| Ever-use | 268 | 1573 | 0.84 (0.73-0.96) | 0.70 (0.61-0.81) |
| Long-term use (≥5 y) | 43 | 375 | 0.57 (0.42-0.79) | 0.45 (0.33-0.63) |
| Cumulative treatment duration | ||||
| <1 y | 86 | 465 | 0.91 (0.72-1.15) | 0.79 (0.62-1.00) |
| 1-4.99 y | 139 | 733 | 0.93 (0.77-1.12) | 0.78 (0.64-0.95) |
| 5-9.99 y | 31 | 287 | 0.53 (0.37-0.77) | 0.42 (0.29-0.61) |
| ≥10 y | 12 | 88 | 0.67 (0.37-1.23) | 0.56 (0.30-1.03) |
| Subgroup . | Cases, n . | Controls, n . | OR∗ (95% CI) . | Adjusted OR† (95% CI) . |
|---|---|---|---|---|
| Exposure | ||||
| Never-use | 3548 | 17 507 | 1.0 (reference) | 1.0 (reference) |
| Ever-use | 268 | 1573 | 0.84 (0.73-0.96) | 0.70 (0.61-0.81) |
| Long-term use (≥5 y) | 43 | 375 | 0.57 (0.42-0.79) | 0.45 (0.33-0.63) |
| Cumulative treatment duration | ||||
| <1 y | 86 | 465 | 0.91 (0.72-1.15) | 0.79 (0.62-1.00) |
| 1-4.99 y | 139 | 733 | 0.93 (0.77-1.12) | 0.78 (0.64-0.95) |
| 5-9.99 y | 31 | 287 | 0.53 (0.37-0.77) | 0.42 (0.29-0.61) |
| ≥10 y | 12 | 88 | 0.67 (0.37-1.23) | 0.56 (0.30-1.03) |
NSAIDs, nonsteroidal anti-inflammatory drugs.
Adjusted for age, sex, and calendar time.
Adjusted for in addition to the following: (1) education level (primary school; high school; short/middle long education; long education); (2) CCI (0; 1; ≥2); (3) previous use of aspirin or other NSAIDs; alendronate; immunosuppressants; and statins; and (4) history of alcohol-related diagnoses, overweight and obesity-related diagnoses, chronic obstructive pulmonary disease, and AD.